Tempus AI Launches ArteraAI Prostate Test for Metastatic Hormone-Sensitive Prostate Cancer

Tempus AI (TEM) has launched the ArteraAI Prostate Test, a CLIA-certified and CAP-accredited prognostic tool designed to assess risk of prostate cancer-specific mortality. The test is available as an add-on within Tempus' solid tumor portfolio and integrates with NGS assay results for comprehensive disease analysis.

By Faheem Tahir Sun, May 24, 2026 at 4:06 PM GMT+3 2 min read · Yahoo Finance · May 24, 2026, 13:06 UTC

Tickers: $BMY $TEM

Topics: AI clinical testing digital pathology prostate cancer

Read the full article at Yahoo Finance

More Health news

Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC
Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths Seeking Alpha · October 29, 2026, 16:18 UTC